Pharma Focus Asia
KP - Choose our fully recyclable blister films

High Concentration Antibody - Rituximab


Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application. The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at 100 mg/ml, whilst maintaining the pH of the original product to minimise the risk of increased rate of chemical instability

ArestatT solution

Rituximab, currently a liquid product, was reformulated into an aqueous presentation at 100 mg/ml based on the ArestatT formulation tools. The control was based on a marketed formulation, working at the same concentration. Improved formulations of rituximab were achieved by application of a recently discovered variant of ArestatT technology, namely Arestat-CT. Using the principles of the Arestat-CT formulation tools, rituximab formulated at 100 mg/ml and placed on storage trial for 12 weeks at 40?C had considerably lower rates of aggregation (formation of high molecular weight species - HMWS, measured by size-exclusion chromatography) compared with that of the control


Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024